Published online Jul 19, 2021. doi: 10.5498/wjp.v11.i7.316
Peer-review started: December 17, 2020
First decision: March 30, 2021
Revised: May 16, 2021
Accepted: June 28, 2021
Article in press: June 28, 2021
Published online: July 19, 2021
Core Tip: We searched MEDLINE and Google Scholar to find articles related to the cardiovascular effects of selective serotonin reuptake inhibitors (SSRIs) in patients with schizophrenia (SCZ) who are taking antipsychotics. We found evidence showing that fluvoxamine reduces metabolic factors in patients taking clozapine, but we also found that SSRIs as a group cause significant yet small increments in metabolic factors. There is also evidence that the effect of SSRIs on metabolic factors depends on which antipsychotics the patient is concurrently taking. Further research in this area is needed before any firm conclusion can be reached on whether SSRIs are beneficial or harmful for cardiovascular risk in SCZ.